example 13 [WO2009109743]

Ligand id: 9077

Name: example 13 [WO2009109743]

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 80.24
Molecular weight 347.14
XLogP 4.55
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
One of the compounds claimed in Vernalis' patent WO2009109743 [2] is likely be V158866, an FAAH inhibitor evaluated in clinical trials. Phase I V158866 results are published in [1]. A Phase II trial in patients with central neuropathic pain following spinal cord injury has been completed (see NCT01748695), but due to a lack of efficacy, Vernalis has suspended further development of V158866.
Mechanism Of Action and Pharmacodynamic Effects
FAAH breaks down fatty acid amides such as anandamide (N-arachidonoylethanolamine, AEA), N-oleoylethanolamide and oleamide. Inhibitors of FAAH lead to elevated anandamide levels and modulate activation of the cannabinoid receptor pathway. This mechanism has been proposed as a novel way to treat pain.